New ALS drug trial aims to tame inflammation
NCT ID NCT07396818
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests an oral drug, Kamlanoflast, in 40 people with ALS. Over 24 weeks, researchers will check safety, tolerability, and whether the drug reduces inflammation and slows decline in function. It is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Kamlanoflast (oral drug)
- What this could lead to
- If it works, this could point toward a treatment that slows ALS progression by reducing inflammation.
- What could go wrong
- This is a very early, small trial (40 people) testing safety and biological effects. It may not show meaningful benefit, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Could sharing lived experiences ease the burden of dementia care?
- Wrist sensors and cameras could revolutionize rehab documentation
- Blood markers may unlock early ALS detection — a study puts them to the test
- Brain implant aims to give voice to those trapped in silence